The report discusses the challenges faced by biopharma companies in funding lower-priority clinical trials. These companies have been successful in research and development, but are now struggling to develop all assets in their pipelines in a timely manner due to limited resources. As a result, they are forced to prioritize their development dollars and delay lower-priority clinical studies, which can reduce the value of assets and revenue potential. The report suggests that exploring a new mechanism to fund the timely execution of deprioritized trials could be a solution to this problem.
